Assessment of nerve excitability in toxic and metabolic neuropathies

Journal of the Peripheral Nervous System

Volumn 13, Issue 1, 2008, Pages 7-26

  Krishnan, Arun V ^a   Lin, Cindy S Y ^a   Park, Susanna B ^a   Kiernan, Matthew C ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Diabetic neuropathy; Nerve excitability; Oxaliplatin; Porphyria; Uremic neuropathy

Indexed keywords

CISPLATIN; OXALIPLATIN; PACLITAXEL; POTASSIUM CHANNEL; SODIUM CHANNEL; TETRODOTOXIN;

ACTION POTENTIAL; CLINICAL ASSESSMENT; COLORECTAL CANCER; CONFERENCE PAPER; DIABETIC NEUROPATHY; DISEASE COURSE; DRUG EFFECT; DYSESTHESIA; ELECTROPHYSIOLOGY; FASCICULATION; FUNCTIONAL DISEASE; HUMAN; KIDNEY FAILURE; MOTOR NEUROPATHY; MOUTH PAIN; MUSCLE RIGIDITY; MUSCLE SPASM; NERVE CONDUCTION; NERVE EXCITABILITY; NERVE FIBER; NERVE STIMULATION; NEUROLOGIC DISEASE; NEUROPATHY; NEUROTOXICITY; NONHUMAN; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SENSORY DYSFUNCTION; SENSORY NERVE; SENSORY NEUROPATHY; SORE THROAT; SYMPTOMATOLOGY; TETANIC SPASM; UREMIC POLYNEUROPATHY;

ACTION POTENTIALS; ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; ION CHANNELS; NERVE TISSUE; PERIPHERAL NERVES; POLYNEUROPATHIES;

EID: 40849134151     PISSN: 10859489     EISSN: 15298027     Source Type: Journal    
DOI: 10.1111/j.1529-8027.2008.00155.x     Document Type: Conference Paper

References (160)

1. Ackil AA, Shahani BT, Young RR, Rubin NE (1981). Late response and sural conduction studies. Usefulness in patients with chronic renal failure. Arch Neurol 38 : 482 485.
2. Adelsberger H, Quasthoff S, Grosskreutz J, Lepier A, Eckel F, Lersch C (2000). The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. Eur J Pharmacol 406 : 25 32.
3. Albers JW, Fink JK (2004). Porphyric neuropathy. Muscle Nerve 30 : 410 422.
4. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A, MOSAIC Investigators (2004). Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350 : 2343 2351.
5. Angus-Leppan H, Burke D (1992). The function of large and small nerve fibers in renal failure. Muscle Nerve 15 : 288 294.
6. Applegate C, Burke D (1989). Changes in excitability of human cutaneous afferents following prolonged high-frequency stimulation. Brain 112 : 147 164.
7. Armand JP, Boige V, Raymond E, Fizazi K, Faivre S, Ducreux M (2000). Oxaliplatin in colorectal cancer: an overview. Semin Oncol 27 : 96 104.
8. Babb AL, Popovich RP, Christopher TG, Scribner BH (1971). The genesis of the square meter-hour hypothesis. ASAIO Trans 17 : 81 91.
9. Babb AL, Ahmad S, Bergstrom J, Scribner BH (1981). The middle molecule hypothesis in perspective. Am J Kidney Dis 1 : 46 50.
10. + currents in sensory neurons. J Neurophysiol 80 : 2538 2549.
11. Baker MD, Bostock H (1999). The pH dependence of late sodium current in large sensory neurons. Neuroscience 92 : 1119 1130.
12. Baker M, Bostock H, Grafe P, Martius P (1987). Function and distribution of three types of rectifying channel in rat spinal root myelinated axons. J Physiol (Lond) 383 : 45 67.
13. Barrett EF, Barrett JN (1982). Intracellular recording from vertebrate myelinated axons: mechanism of the depolarizing afterpotential. J Physiol (Lond) 323 : 117 144.
14. Becker D, Viljoen D, Kramer S (1971). The inhibition of red cell and brain ATPase by delta-aminolaevulinic acid. Biochim Biophys Acta 225 : 26 34.
15. Bergmans J (1970). The Physiology of Single Human Nerve Fibres. University of Louvain, Vander, Belgium.
16. Birch BD, Kocsis JD, Di Gregorio F, Bhisitkul RB, Waxman SG (1991). A voltage- and time-dependent rectification in rat dorsal spinal root axons. J Neurophysiol 66 : 719 728.
17. Bittar EE (1967). Maia muscle fibre as a model for the study of uraemic toxicity. Nature 214 : 310 312.
18. Bolton CF (1980). Peripheral neuropathies associated with chronic renal failure. Can J Neurol Sci 7 : 89 96.
19. Bostock H (1983). The strength-duration relationship for excitation of myelinated nerve: computed dependence on membrane parameters. J Physiol 341 : 59 74.
20. Bostock H (1993). Impulse Propagation in Experimental Neuropathy. In : Peripheral Neuropathy. Dyck PJ, Thomas PK, Griffin JW, Low PA, Poduslo JF (Eds). Saunders, Philadelphia, pp 109 120.
21. Bostock H, Bergmans J (1994). Post-tetanic excitability changes and ectopic discharges in a human motor axon. Brain 117 : 913 928.
22. Bostock H, Grafe P (1985). Activity-dependent excitability changes in normal and demyelinated rat spinal root axons. J Physiol (Lond) 365 : 239 257.
23. Bostock H, Rothwell JC (1997). Latent addition in motor and sensory fibres of human peripheral nerve. J Physiol (Lond) 498 : 277 294.
24. Bostock H, Burke D, Hales JP (1994). Differences in behaviour of sensory and motor axons following release of ischaemia. Brain 117 : 225 234.
25. Bostock H, Cikurel K, Burke D (1998). Threshold tracking techniques in the study of human peripheral nerve. Muscle Nerve 21 : 137 158.
26. Bostock H, Walters RJ, Andersen KV, Murray NM, Taube D, Kiernan MC (2004). Has potassium been prematurely discarded as a contributing factor to the development of uraemic neuropathy? Nephrol Dial Transplant 19 : 1054 1057.
27. Brismar T (1993). Abnormal Na-currents in diabetic rat nerve nodal membrane. Diabet Med 10 : 110S 112S.
28. Brismar T, Sima AA (1981). Changes in nodal function in nerve fibres of the spontaneously diabetic BB-Wistar rat: potential clamp analysis. Acta Physiol Scand 113 : 499 506.
29. Brismar T, Sima AA, Greene DA (1987). Reversible and irreversible nodal dysfunction in diabetic neuropathy. Ann Neurol 21 : 504 507.
30. Burke D, Kiernan MC, Bostock H (2001). Excitability of human axons. Clin Neurophysiol 112 : 1575 1585.
31. Caldwell JH, Schaller KL, Lasher RS, Peles E, Levinson SR (2000). Sodium channel Na(v)1.6 is localized at nodes of Ranvier, dendrites, and synapses. Proc Natl Acad Sci USA 97 : 5616 5620.
32. Cappelen-Smith C, Kuwabara S, Lin CS, Mogyoros I, Burke D (2000). Activity-dependent hyperpolarization and conduction block in chronic inflammatory demyelinating polyneuropathy. Ann Neurol 48 : 826 832.
33. Cappelen-Smith C, Kuwabara S, Lin CS, Mogyoros I, Burke D (2001). Membrane properties in chronic inflammatory demyelinating polyneuropathy. Brain 124 : 2439 2447.
34. Cassidy J, Misset J-L (2002). Oxaliplatin-related side effects: characteristics and management. Semin Oncol 29 : 11 20.
35. Catterall WA (1992). Cellular and molecular biology of voltage-gated sodium channels. Physiol Rev 72 : S15 S48.
36. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000). Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18 : 2938 2947.
37. Duchen MR (1990). Effects of metabolic inhibition on the membrane properties of isolated mouse primary sensory neurones. J Physiol (Lond) 424 : 387 409.
38. Felts PA, Kapoor R, Smith KJ (1995). A mechanism for ectopic firing in central demyelinated axons. Brain 118 : 1225 1231.
39. Gamelin E, Gamelin L, Bossi L, Quasthoff S (2002). Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 29 : 21 33.
40. Gilliatt RW, Willison RG (1963). The refractory and supernormal periods of the human median nerve. J Neurol Neurosurg Psychiatry 26 : 136 147.
41. Ginn HE, Bugel HJ, James L, Hopkins P (1971). Clinical experience with small surface area dialyzers (SSAD). Proc Clin Dial Transplant Forum 1 : 53 60.
42. +/K(+)-ATPase) activity in rat optic nerve. Neuroscience 37 : 829 837.
43. Greene DA (1986). A sodium-pump defect in diabetic peripheral nerve corrected by sorbinil administration: relationship to myo-inositol metabolism and nerve conduction slowing. Metabolism 35 : 60 65.
44. Greene DA, Lattimer SA (1984). Impaired energy utilization and Na-K-ATPase in diabetic peripheral nerve. Am J Physiol 246 : E311 E318.
45. Greene DA, Lattimer SA, Sima AA (1987). Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications. N Engl J Med 316 : 599 606.
46. +-ATPase regulation involved in pathogenesis of diabetic neuropathy? Diabetes 37 : 688 693.
47. Grothey A (2003). Oxaliplatin-safety profile: neurotoxicity. Semin Oncol 30 : 5 13.
48. Hart IK, Maddison P, Newsom-Davis J, Vincent A, Mills KR (2002). Phenotypic variants of autoimmune peripheral nerve hyperexcitability. Brain 125 : 1887 1895.
49. Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F (2006). Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol 33 : 15 49.
50. Herzog RI, Cummins TR, Ghassemi F, Dib-Hajj SD, Waxman SG (2003). Distinct repriming and closed-state inactivation kinetics of Nav1.6 and Nav1.7 sodium channels in mouse spinal sensory neurons. J Physiol (Lond) 551 : 741 750.
51. Hodgkin AL, Huxley AF (1952). A quantitative description of membrane current and its application to conduction and excitation in nerve. J Physiol (Lond) 117 : 500 544.
52. Hohman TC, Cotter MA, Cameron NE (2000). ATP-sensitive K(+) channel effects on nerve function, Na(+), K(+) ATPase, and glutathione in diabetic rats. Eur J Pharmacol 397 : 335 341.
53. Isbister GK, Kiernan MC (2005). Neurotoxic marine poisoning. Lancet Neurol 4 : 219 228.
54. Kaji R (2003). Physiology of conduction block in multifocal motor neuropathy and other demyelinating neuropathies. Muscle Nerve 27 : 285 296.
55. Kaji R, Sumner AJ (1989). Ouabain reverses conduction disturbances in single demyelinated nerve fibers. Neurology 39 : 1364 1368.
56. Kaji R, Bostock H, Kohara N, Murase N, Kimura J, Shibasaki H (2000). Activity-dependent conduction block in multifocal motor neuropathy. Brain 123 : 1602 1611.
57. Kanai K, Kuwabara S, Arai K, Sung JY, Ogawara K, Hattori T (2003). Muscle cramp in Machado-Joseph disease: altered motor axonal excitability properties and mexiletine treatment. Brain 126 : 965 973.
58. Kanai K, Kuwabara S, Misawa S, Tamura N, Ogawara K, Nakata M, Sawai S, Hattori T, Bostock H (2006). Altered axonal excitability properties in amyotrophic lateral sclerosis: impaired potassium channel function related to disease stage. Brain 129 : 953 962.
59. Kiernan MC (2006). Back to the future: excitability studies take on a new clinical role. Clin Neurophysiol 117 : 712 713.
60. Kiernan MC, Bostock H (2000). Effects of membrane polarization and ischaemia on the excitability properties of human motor axons. Brain 123 : 2542 2551.
61. Kiernan MC, Krishnan AV (2006). The pathophysiology of oxaliplatin-induced neurotoxicity. Curr Med Chem 13 : 2901 2907.
62. Kiernan MC, Mogyoros I, Burke D (1996). Differences in the recovery of excitability in sensory and motor axons of human median nerve. Brain 119 : 1099 1105.
63. Kiernan MC, Mogyoros I, Burke D (1999). Conduction block in carpal tunnel syndrome. Brain 122 : 933 941.
64. Kiernan MC, Burke D, Andersen KV, Bostock H (2000). Multiple measures of axonal excitability: a new approach in clinical testing. Muscle Nerve 23 : 399 409.
65. Kiernan MC, Lin CS, Andersen KV, Murray NM, Bostock H (2001a). Clinical evaluation of excitability measures in sensory nerve. Muscle Nerve 24 : 883 892.
66. Kiernan MC, Cikurel K, Bostock H (2001b). Effects of temperature on the excitability properties of human motor axons. Brain 124 : 816 825.
67. Kiernan MC, Hart IK, Bostock H (2001c). Excitability properties of motor axons in patients with spontaneous motor unit activity. J Neurol Neurosurg Psychiatry 70 : 56 64.
68. Kiernan MC, Guglielmi JM, Kaji R, Murray NM, Bostock H (2002a). Evidence for axonal membrane hyperpolarization in multifocal motor neuropathy with conduction block. Brain 125 : 664 675.
69. Kiernan MC, Walters RJ, Andersen KV, Taube D, Murray NM, Bostock H (2002b). Nerve excitability changes in chronic renal failure indicate membrane depolarization due to hyperkalaemia. Brain 125 : 1366 1378.
70. Kiernan MC, Lin CS, Burke D (2004). Differences in activity-dependent hyperpolarization in human sensory and motor axons. J Physiol 558 : 341 349.
71. Kiernan MC, Isbister GK, Lin CS-Y, Burke D, Bostock H (2005a). Acute tetrodotoxin-induced neurotoxicity after ingestion of puffer fish. Ann Neurol 57 : 339 348.
72. + channel subunit SCN1B produces paradoxical changes in peripheral nerve excitability. Brain 128 : 1841 1846.
73. Kiernan MC, Burke D, Bostock H (2005c). Nerve Excitability Measures: Biophysical Basis and Use in the Investigation of Peripheral Nerve Disease. In : Peripheral Neuropathy. Dyck PJ, Thomas PK (Eds). Elsevier Saunders, Philadelphia, pp 113 130.
74. Kitano Y, Kuwabara S, Misawa S, Ogawara K, Kanai K, Kikkawa Y, Yagui K, Hattori T (2004). The acute effects of glycemic control on axonal excitability in human diabetics. Ann Neurol 56 : 462 467.
75. Krarup-Hansen A, Rietz B, Krarup C, Heydorn K, Rorth M, Schmalbruch H (1999). Histology and platinum content of sensory ganglia and sural nerves in patients treated with cisplatin and carboplatin: an autopsy study. Neuropathol Appl Neurobiol 25 : 29 40.
76. Krarup-Hansen A, Helweg-Larsen S, Schmalbruch H, Rorth M, Krarup C (2007). Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies. Brain 130 : 1076 1088.
77. Krishnan AV, Kiernan MC (2005). Altered nerve excitability properties in established diabetic neuropathy. Brain 128 : 1178 1187.
78. Krishnan AV, Kiernan MC (2006). Axonal function and activity-dependent excitability changes in myotonic dystrophy. Muscle Nerve 33 : 627 636.
79. Krishnan AV, Kiernan MC (2007). Uremic neuropathy: clinical features and new pathophysiological insights. Muscle Nerve 35 : 273 290.
80. Krishnan AV, Lin CS, Kiernan MC (2004). Nerve excitability properties in lower-limb motor axons: evidence for a length-dependent gradient. Muscle Nerve 29 : 645 655.
81. Krishnan AV, Phoon RK, Pussell BA, Charlesworth JA, Bostock H, Kiernan MC (2005a). Altered motor nerve excitability in end-stage kidney disease. Brain 128 : 2164 2174.
82. Krishnan AV, Colebatch JG, Kiernan MC (2005b). Hypokalemic weakness in hyperaldosteronism: activity-dependent conduction block. Neurology 65 : 1309 1312.
83. Krishnan AV, Goldstein D, Friedlander M, Kiernan MC (2005c). Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve 32 : 51 60.
84. Krishnan AV, Phoon RK, Pussell BA, Charlesworth JA, Bostock H, Kiernan MC (2006a). Ischaemia induces paradoxical changes in axonal excitability in end-stage kidney disease. Brain 129 : 1585 1592.
85. + pump function and activity-dependent excitability changes in end-stage kidney disease. Clin Neurophysiol 117 : 992 999.
86. + channel function in vivo. Clin Cancer Res 12 : 4481 4484.
87. Krishnan AV, Phoon RK, Pussell BA, Charlesworth JA, Kiernan MC (2006d). Sensory nerve excitability and neuropathy in end stage kidney disease. J Neurol Neurosurg Psychiatry 77 : 548 551.
88. Krishnan AV, Hayes M, Kiernan MC (2007). Axonal excitability properties in hemifacial spasm. Mov Disord 22 : 1293 1298.
89. Krishnan AV, Bostock H, Ip J, Hayes M, Watson SR, Kiernan MC (in press). Axonal function in a family with episodic ataxia type 2 due to a novel mutation. J Neurol.
90. Kuebler JP, Wieand HS, O'Connell MJ, Smith RE, Colangelo LH, Yothers G, Petrelli NJ, Findlay MP, Seay TE, Atkins JN, Zapas JL, Goodwin JW, Fehrenbacher L, Ramanathan RK, Conley BA, Flynn PJ, Soori G, Colman LK, Levine EA, Lanier KS, Wolmark N (2007). Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for Stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 25 : 2198 2204.
91. Kugelberg E (1944). Accommodation in human nerves and its significance for the symptoms in circulatory disturbances and tetany. Acta Physiol Scand 8 : 1 105.
92. Kuwabara S, Ogawara K, Harrori T, Suzuki Y, Hashimoto N (2002a). The acute effects of glycemic control on axonal excitability in human diabetic nerves. Intern Med 41 : 360 365.
93. Kuwabara S, Kanai K, Sung JY, Ogawara K, Hattori T, Burke D, Bostock H (2002b). Axonal hyperpolarization associated with acute hypokalemia: multiple excitability measurements as indicators of the membrane potential of human axons. Muscle Nerve 26 : 283 287.
94. Kuwabara S, Ogawara K, Sung JY, Mori M, Kanai K, Hattori T, Yuki N, Lin CS, Burke D, Bostock H (2002c). Differences in membrane properties of axonal and demyelinating Guillain-Barre syndromes. Ann Neurol 52 : 180 187.
95. Laaksonen S, Metsarinne K, Voipio-Pulkki LM, Falck B (2002). Neurophysiologic parameters and symptoms in chronic renal failure. Muscle Nerve 25 : 884 890.
96. Lee JJ, Swain SM (2006). Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 24 : 1633 1642.
97. Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK (2004). Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 29 : 387 392.
98. Lin CS, Macefield VG, Elam M, Wallin BG, Engel S, Kiernan MC (2007). Axonal changes in spinal cord injured patients distal to the site of injury. Brain 130 : 985 994.
99. Lin CSY, Kuwabara S, Cappelen-Smith C, Burke D (2002). Responses of human sensory and motor axons to the release of ischaemia and to hyperpolarizing currents. J Physiol 541 : 1025 1039.
100. Lin CSY, Krishnan AV, Lee M-J, Zagami AS, Kiernan MC (in press). Axonal function in acute intermittent porphyria. Clin Neurophys.
101. LoMonaco M, Milone M, Batocchi AP, Padua L, Restuccia D, Tonali P (1992). Cisplatin neuropathy: clinical course and neurophysiological findings. J Neurol 239 : 199 204.
102. Low PA, Schmelzer JD, Ward KK, Yao JK (1986). Experimental chronic hypoxic neuropathy: relevance to diabetic neuropathy. Am J Physiol 250 : E94 E99.
103. Low PA, Lagerlund TD, McManis PG (1989). Nerve blood flow and oxygen delivery in normal, diabetic, and ischemic neuropathy. Int Rev Neurobiol 31 : 355 438.
104. Mackel R, Brink E (2003). Conduction of neural impulses in diabetic neuropathy. Clin Neurophysiol 114 : 248 255.
105. Man NK, Granger A, Rondon-Nucete M, Zingraff J, Jungers P, Sausse A, Funck-Brentano JL (1973). One year follow-up of short dialysis with a membrane highly permeable to middle molecules. Proc Eur Dial Transplant Assoc 10 : 236 246.
106. McDonald ES, Windebank AJ (2002). Cisplatin-induced apoptosis of DRG neurons involves bax redistribution and cytochrome c release but not fas receptor signaling. Neurobiol Dis 9 : 220 233.
107. Misawa S, Kuwabara S, Ogawara K, Kitano Y, Yagui K, Hattori T (2004). Hyperglycemia alters refractory periods in human diabetic neuropathy. Clin Neurophysiol 115 : 2525 2529.
108. + currents and nerve conduction in human diabetics. Neurology 66 : 1545 1549.
109. Mogyoros I, Kiernan MC, Burke D (1996). Strength-duration properties of human peripheral nerve. Brain 119 : 439 447.
110. Mogyoros I, Kiernan MC, Burke D (1997). Strength-duration properties of sensory and motor axons in carpal tunnel syndrome. Muscle Nerve 20 : 508 510.
111. Mogyoros I, Lin C, Dowla S, Grosskreutz J, Burke D (1999). Strength-duration properties and their voltage dependence at different sites along the median nerve. Clin Neurophysiol 110 : 1618 1624.
112. Mollman JE (1990). Cisplatin neurotoxicity. N Engl J Med 322 : 126 127.
113. Ng K, Lin CS, Murray NM, Burroughs AK, Bostock H (2007). Conduction and excitability properties of peripheral nerves in end-stage liver disease. Muscle Nerve 35 : 730 738.
114. Nielsen VK (1973a). The peripheral nerve function in chronic renal failure. V. Sensory and motor conduction velocity. Acta Med Scand 194 : 445 454.
115. Nielsen VK (1973b). The peripheral nerve function in chronic renal failure. VI. The relationship between sensory and motor nerve conduction and kidney function, azotemia, age, sex, and clinical neuropathy. Acta Med Scand 194 : 455 462.
116. Nodera H, Bostock H, Kuwabara S, Sakamoto T, Asanuma K, Jia-Ying S, Ogawara K, Hattori N, Hirayama M, Sobue G, Kaji R (2004). Nerve excitability properties in Charcot-Marie-Tooth disease type 1A. Brain 127 : 203 211.
117. Nukada H (1986). Increased susceptibility to ischemic damage in streptozocin-diabetic nerve. Diabetes 35 : 1058 1061.
118. Nukada H (1992). Mild ischemia causes severe pathological changes in experimental diabetic nerve. Muscle Nerve 15 : 1116 1122.
119. + channels. Jpn J Pharmacol 88 : 365 377.
120. Park SB, Lin CS-Y, Krishnan AV, Friedlander M, Goldstein D, Kiernan MC (in press). Oxaliplatin-induced chronic changes in sensory nerve excitability. Clin Neurophys.
121. Parry GJ, Kohzu H (1989). Studies of resistance to ischemic nerve conduction failure in normal and diabetic rats. J Neurol Sci 93 : 61 67.
122. Pietrangeli A, Leandri M, Terzoli E, Jandolo B, Garufi C (2006). Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up. Eur Neurol 56 : 13 16.
123. Quasthoff S, Hartung HP (2002). Chemotherapy-induced peripheral neuropathy. J Neurol 249 : 9 17.
124. Rakowski RF, Gadsby DC, De Weer P (1989). Stoichiometry and voltage dependence of the sodium pump in voltage-clamped, internally dialyzed squid giant axon. J Gen Physiol 93 : 903 941.
125. Raymond E, Faivre S, Woynarowski JM, Chaney SG (1998). Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 25 : 4 12.
126. Ritchie J, Straub R (1957). The hyperpolarization which follows activity in mammalian non-medullated fibres. J Physiol (Lond) 136 : 80 97.
127. Roper J, Schwarz JR (1989). Heterogeneous distribution of fast and slow potassium channels in myelinated rat nerve fibres. J Physiol (Lond) 416 : 93 110.
128. +-ATPase activity by delta-aminolevulinic acid. Neurochem Res 8 : 1407 1415.
129. Sahenk Z, Barohn R, New P, Mendell JR (1994). Taxol neuropathy: electrodiagnostic and sural nerve biopsy findings. Arch Neurol 51 : 726 729.
130. Schilling T, Heinrich B, Kau R, Herzog M, Quasthoff S, Diergarten K, Rastetter J, Hanauske AR (1997). Paclitaxel administered over 3h followed by cisplatin in patients with advanced head and neck squamous cell carcinoma: a clinical phase I study. Oncology 54 : 89 95.
131. Schneider U, Niedermeier W, Grafe P (1993). The paradox between resistance to hypoxia and liability to hypoxic damage in hyperglycemic peripheral nerves. Evidence for glycolysis involvement. Diabetes 42 : 981 987.
132. Seneviratne KN, Peiris OA (1968). The effect of ischaemia on the excitability of sensory nerves in diabetes mellitus. J Neurol Neurosurg Psychiatry 31 : 348 353.
133. Silva A, Wang Q, Wang M, Ravula SK, Glass JD (2006). Evidence for direct axonal toxicity in vincristine neuropathy. J Peripher Nerv Syst 11 : 211 216.
134. Sima AA (1996). Metabolic alterations of peripheral nerve in diabetes. Semin Neurol 16 : 129 137.
135. Steiness I (1959). Vibratory perception in diabetics during arrested blood flow to the limb. Acta Med Scand 163 : 195 205.
136. Stevens MJ, Lattimer SA, Kamijo M, Van Huysen C, Sima AA, Greene DA (1993). Osmotically-induced nerve taurine depletion and the compatible osmolyte hypothesis in experimental diabetic neuropathy in the rat. Diabetologia 36 : 608 614.
137. Stevens MJ, Feldman EL, Greene DA (1995). The aetiology of diabetic neuropathy: the combined roles of metabolic and vascular defects. Diabet Med 12 : 566 579.
138. Strupp M, Bostock H, Weigl P, Piwernetz K, Renner R, Grafe P (1990). Is resistance to ischaemia of motor axons in diabetic subjects due to membrane depolarization? J Neurol Sci 99 : 271 280.
139. Taddese A, Bean BP (2002). Subthreshold sodium current from rapidly inactivating sodium channels drives spontaneous firing of tuberomammillary neurons. Neuron 33 : 587 600.
140. Tan SV, Lee PJ, Walters RJ, Mehta A, Bostock H (2005). Evidence for motor axon depolarization in Fabry disease. Muscle Nerve 32 : 548 551.
141. + conductance in peripheral axons. Muscle Nerve 28 : 212 217.
142. Vagg R, Mogyoros I, Kiernan MC, Burke D (1998). Activity-dependent hyperpolarization of human motor axons produced by natural activity. J Physiol (Lond) 507 : 919 925.
143. Van den Neucker K, Vanderstraeten G, Vanholder R (1998). Peripheral motor and sensory nerve conduction studies in haemodialysis patients. A study of 54 patients. Electromyogr Clin Neurophysiol 38 : 467 474.
144. Vanholder R, De Smet R, Hsu C, Vogeleere P, Ringoir S (1994). Uremic toxicity: the middle molecule hypothesis revisited. Semin Nephrol 14 : 205 218.
145. Vucic S, Kiernan MC (2006a). Axonal excitability properties in amyotrophic lateral sclerosis. Clin Neurophysiol 117 : 1458 1466.
146. Vucic S, Kiernan MC (2006b). Novel threshold tracking techniques suggest that cortical hyperexcitability is an early feature of MND. Brain 129 : 2436 2446.
147. Vucic S, Kiernan MC (2007). Pathophysiologic insights into motor axonal function in Kennedy disease. Neurology 69 : 1828 1835.
148. Vucic S, Kiernan MC (2008). Normal axonal ion channel function in large peripheral nerve fibers following chronic ciguatera sensitization. Muscle Nerve 37 : 403 405.
149. Wahren J, Ekberg K, Johansson J, Henriksson M, Pramanik A, Johansson BL, Rigler R, Jornvall H (2000). Role of C-peptide in human physiology. Am J Physiol Endocrinol Metab 278 : E759 E768.
150. Waxman SG, Ritchie JM (1993). Molecular dissection of the myelinated axon. Ann Neurol 33 : 121 136.
151. Webster RG, Brain KL, Wilson RH, Grem JL, Vincent A (2005). Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br J Pharmacol 146 : 1027 1039.
152. Weigl P, Bostock H, Franz P, Martius P, Muller W, Grafe P (1989). Threshold tracking provides a rapid indication of ischaemic resistance in motor axons of diabetic subjects. Electroencephalogr Clin Neurophysiol 73 : 369 371.
153. Weiss G (1901). Sur la possibilité de rendre comparables entre eux les appareils servant l'excitation électrique. Arch Ital Biol 35 : 413 446.
154. Welt LG, Sachs JR, McManus TJ (1964). An ion transport defect in erythrocytes from uraemic subjects. Trans Ass Am Phys 77 : 169 181.
155. Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter MK, Grem JL (2002). Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 20 : 1767 1774.
156. Yang CC, Liao SC, Deng JF, Yang CC, Liao SC, Deng JF (1996). Tetrodotoxin poisoning in Taiwan: an analysis of poison center data. Vet Hum Toxicol 38 : 282 286.
157. Z'Graggen WJ, Lin CS, Howard RS, Beale RJ, Bostock H (2006). Nerve excitability changes in critical illness polyneuropathy. Brain 129 : 2461 2470.
158. Zhang W, Yorek M, Pierson CR, Murakawa Y, Breidenbach A, Sima AA (2001). Human C-peptide dose dependently prevents early neuropathy in the BB/Wor-rat. Int J Exp Diabetes Res 2 : 187 193.
159. Zhu X, Eichberg J (1990a). 1,2-Diacylglycerol content and its arachidonyl-containing molecular species are reduced in sciatic nerve from streptozotocin-induced diabetic rats. J Neurochem 55 : 1087 1090.
160. Zhu X, Eichberg J (1990b). A myo-inositol pool utilized for phosphatidylinositol synthesis is depleted in sciatic nerve from rats with streptozotocin-induced diabetes. Proc Natl Acad Sci USA 87 : 9818 9822.